|1.||Meyer zu Hörste, Gerd: 3 articles (01/2011 - 02/2009)|
|2.||Kieseier, Bernd C: 3 articles (01/2011 - 02/2009)|
|3.||Mausberg, Anne K: 3 articles (01/2011 - 02/2009)|
|4.||Stüve, Olaf: 3 articles (01/2011 - 02/2009)|
|5.||Korth, Carsten: 3 articles (01/2011 - 02/2009)|
|6.||Löber, Stefan: 2 articles (01/2011 - 02/2009)|
|7.||Gmeiner, Peter: 2 articles (01/2011 - 02/2009)|
|8.||Lehmann, Helmar C: 1 article (01/2011)|
|9.||Hartung, Hans-Peter: 1 article (01/2011)|
|10.||Müller, Johanna I: 1 article (01/2011)|
06/01/2009 - "Quinpramine: revival of old anti-inflammatory principles in multiple sclerosis?"
02/01/2009 - "Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. "
|2.||Experimental Autoimmune Neuritis
01/01/2011 - "Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules."
01/01/2011 - "We studied the immunological and clinical effects of quinpramine in myelin homogenate induced Lewis rat experimental autoimmune neuritis (EAN), a model system for acute human inflammatory neuropathies, such as the Guillain-Barré syndrome. "
|3.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
06/01/2010 - "The chimeric compound quinpramine-generated from its precursor substances imipramine and quinacrine-has recently demonstrated clinical efficacy in experimental autoimmune encephalomyelitis (EAE), an animal model for MS. Mechanistic considerations and recent experimental data suggest that intracellular redistribution of antigen-presenting molecules and cholesterol-rich membrane domains may account for the clinical efficacy of this drug. "
|4.||Autoimmune Diseases (Autoimmune Disease)
|5.||Demyelinating Diseases (Demyelinating Disease)